The frequency of CD127\textsuperscript{low} expressing CD4\textsuperscript{+}CD25\textsuperscript{high} T regulatory cells is inversely correlated with human T lymphotrophic virus type-I (HTLV-1) proviral load in HTLV-1-infection and HTLV-1-associated myelopathy/tropical spastic paraparesis

Jakob Michaëlsson\textsuperscript{†1,5}, Hugo Marcelo R Barbosa\textsuperscript{†2}, Kimberley A Jordan\textsuperscript{1}, Joan M Chapman\textsuperscript{1}, Milena KC Brunialti\textsuperscript{2}, Walter Kleine Neto\textsuperscript{3}, Youko Nukui\textsuperscript{3}, Ester C Sabino\textsuperscript{3}, Marco Antonio Chieia\textsuperscript{2}, Acary Souza Bulle Oliveira\textsuperscript{2}, Douglas F Nixon\textsuperscript{1} and Esper G Kallas*\textsuperscript{2,4}

Address: \textsuperscript{1}Division of Experimental Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA, \textsuperscript{2}Infectious Diseases Division, Federal University of São Paulo, São Paulo, Brazil, \textsuperscript{3}São Paulo Blood Bank, São Paulo, Brazil, \textsuperscript{4}Clinical Immunology and Allergy Division, University of São Paulo, Brazil and \textsuperscript{5}Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

Email: Jakob Michaëlsson - jakob.michaelsson@ki.se; Hugo Marcelo R Barbosa - hugomarcelo.barbosa@gmail.com; Kimberley A Jordan - kjordan@gmail.com; Joan M Chapman - joanmchapman@yahoo.com; Milena KC Brunialti - milena.brunialti@unifesp.br; Walter Kleine Neto - walterkleine@yahoo.com.br; Youko Nukui - ynukui@terra.com.br; Ester C Sabino - sabinoc@uol.com.br; Marco Antonio Chieia - abrela99@hotmail.com; Acary Souza Bulle Oliveira - abrela99@hotmail.com; Douglas F Nixon - douglas.nixon@ucsf.edu; Esper G Kallas* - kallas.dmed@epm.br

* Corresponding author    \ †Equal contributors

Abstract

Background: CD4\textsuperscript{+}CD25\textsuperscript{high} regulatory T (T\textsubscript{Reg}) cells modulate antigen-specific T cell responses, and can suppress anti-viral immunity. In HTLV-1 infection, a selective decrease in the function of T\textsubscript{Reg} cell mediated HTLV-1-tax inhibition of FOXP3 expression has been described. The purpose of this study was to assess the frequency and phenotype of T\textsubscript{Reg} cells in HTLV-1 asymptomatic carriers and in HTLV-1-associated neurological disease (HAM/TSP) patients, and to correlate with measures of T cell activation.

Results: We were able to confirm that HTLV-1 drives activation, spontaneous IFN\textgamma production, and proliferation of CD4\textsuperscript{+} T cells. We also observed a significantly lower proportion of CTLA-4\textsuperscript{+} T\textsubscript{Reg} cells (CD4\textsuperscript{+}CD25\textsuperscript{high} T cells) in subjects with HAM/TSP patients compared to healthy controls. Ki-67 expression was negatively correlated to the frequency of CTLA-4\textsuperscript{+} T\textsubscript{Reg} cells in HAM/TSP only, although Ki-67 expression was inversely correlated with the percentage of CD127\textsuperscript{low} T\textsubscript{Reg} cells in healthy control subjects. Finally, the proportion of CD127\textsuperscript{low} T\textsubscript{Reg} cells correlated inversely with HTLV-1 proviral load.

Conclusion: Taken together, the results suggest that T\textsubscript{Reg} cells may be subverted in HAM/TSP patients, which could explain the marked cellular activation, spontaneous cytokine production, and proliferation of CD4\textsuperscript{+} T cells, in particular those expressing the CD25\textsuperscript{high}CD127\textsuperscript{low} phenotype. T\textsubscript{Reg} cells represent a potential target for therapeutic intervention for patients with HTLV-1-related neurological diseases.
Background

Between 10 and 20 million people are infected with HTLV-1 worldwide [1]. Although most subjects are clinically asymptomatic during their lifetime, a proportion (5 to 10%) develop adult T cell leukemia/lymphoma (ATLL) or HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) [2]. Epidemiological surveys have identified regions in the world where prevalence rates are considerably higher, including Japan, the Caribbean, South America, Africa, Melanesia and the Middle East [1,3]. It has been estimated that the prevalence of HTLV-1 infection in South America ranges from 2 to 5% [4], with an estimated 1–2 million infected people in Brazil [5]. The prevalence in blood donors ranges from 0.17 to 1.8% in different areas of the country [6,7], with a 0.3% seroprevalence in the city of Sao Paulo blood donors [8].

HTLV-1 is a retrovirus encoding the group specific antigen (gag), protease (pro), polymerase (pol), and envelope (env) genes. Six proteins are encoded by the pX region of the genome, including the Tax protein, which is critical to viral replication and induction of cellular activation and transformation, increasing the expression and production of cytokines and receptors involved in T cell growth and transformation, such as IL-15 [9,10] and IL-2 [11-13]. Tax also has the ability of interfering in the expression of several transcription factors and proto-oncogenes, as well as in the nucleic acid repair and apoptosis [14-17]. These effects combined seem to play a key role in the potential of HTLV-1 to induce cellular transformation and, consequently, trigger the development of ATLL.

It has been previously demonstrated that HTLV-1 proviral load is one of the key factors in the pathogenesis of HAM/TSP [18,19], although host genetic factors are also independently associated with the development of the diseases, e.g. certain HLA [20,21] and non-HLA [22,23] genes. These invoke the hypothesis that both viral and genetic host factors are implicated in the pathogenesis of HAM/TSP.

The CD8+ T cell response to HTLV-1 can be readily detected [24-31], commonly directed against the HTLV-1-tax protein. The contribution of the CD8+ T cell response might be particularly important for viral control in HTLV-1 infection, since infected lymphocytes produce virtually no cell-free infectious HTLV-1 particles. However, it is noteworthy that the magnitude of the HTLV-1-specific T cell response is associated with higher proviral loads, highlighting the fact that T cells frequencies are determined by proviral load, as well as being a determinant of proviral load. CD4+ T cells are the main target for HTLV-1 infection, which induces CD4+ T cell activation, including proliferation and IFNγ production. The HTLV-1-specific CD4+ T cell response is directed mainly against Env, the HTLV-1 envelope surface [32].

TReg cells are crucial for the control of autoimmune disease and maintenance of peripheral T cell tolerance (reviewed in Sakagushi et al. [33]). In addition, they can suppress pathogen-specific T cell responses, including response to viruses [34-37]. The mechanisms whereby TReg cells suppress T cell responses are not yet fully understood, but are likely to include both soluble factors, e.g. IL-10 and TGF-β, as well as cell-cell contact dependent mechanisms, e.g. through CTLA-4. CTLA-4 (CD152) is expressed by a large fraction of CD4+CD25+ T cells, and by a majority of CD4+CD25high T cells. CTLA-4 has also been shown to be one of mediators of TReg function [38,39], and is considered a marker for TReg cells. In addition, it was recently demonstrated that TReg cells are characterized by low levels of the IL-7Rα (CD127low) [40-42], which together with CD25 help to distinguish TReg cells from activated normal CD4+ T cells in healthy individuals. FOXP3 is a key regulator of TReg cell function, but is not exclusive to TReg cells; it has been identified in human nonregulatory activated CD4+FoxP3+ T cells. Humans with mutations in FOXP3 present with a syndrome characterized by severe autoimmune and inflammatory disorders often early in life, denominated IPEX [33]. Interestingly, it was recently shown that HTLV-1 tax can downregulate Foxp3 expression [43,44].

We hypothesized that HTLV-1 compromises TReg cell function, resulting in higher T cell activation, which contributes to HAM/TSP development. We found a significantly higher frequency of CD4+Ki-67+ T cells and a lower proportion of CD4+ TReg cells in subjects with HAM/TSP, compared to healthy controls. Moreover, we found an inverse correlation between HTLV-1 proviral load and frequency of CD127low/CTLA-4+ TReg cells. Our data suggest a role for TReg cells in the pathogenesis of HAM/TSP, and reveal a potential new therapeutic target for patients with HAM/TSP.

Results

Study subjects

Blood samples were collected at the Federal University of Sao Paulo outpatient clinics, after informed consent. PBMC were isolated by Ficoll-Paque PLUS density centrifugation and cryopreserved. The demographics of the study subjects are shown in Table 1, including gender, age, proviral load, CD3, CD4 and CD8 absolute T cell counts. No statistically significant differences were observed in gender and age distribution among groups.
CD4+ T cell activation and IFNγ production in healthy donors, HTLV-1 seropositive asymptomatics, and HAM/TSP patients

We initially investigated the expression of Ki-67, HLA-DR and CD38 on CD4+ T cells in PBMC from healthy donors (Control), HTLV-1 infected patients who were clinically asymptomatic (HTLV), or had associated neurological disease (HAM/TSP). HAM/TSP had significantly higher frequencies of CD4+Ki-67+ T cells compared to HTLV or Control subjects (Fig. 1A, 1C). In addition, HAM/TSP patients had an increase in the frequency of CD4+ HLA-DR+ T cells compared to Controls (Fig. 1E), whereas no statistically significant difference in frequency of CD4+CD38+ T cells was noted (data not shown). Furthermore, CD4+ T cells from both HTLV and HAM/TSP groups had an increase in the spontaneous expression of IFNγ (Fig. 1B, 1D).

Decreased frequency of T\textsubscript{Reg} cells in HAM/TSP patients

In order to assess the frequency of T\textsubscript{Reg} cells in HTLV-1 infected subjects, we measured the expression of CD25, CTLA-4, CD127 and GITR on CD4+ T cells by flow cytometry. Gating strategies are shown in Fig. 2A–C. The frequency of CD4+ T cells expressing CD25 was very similar between the groups (Fig. 2D). As CD25 is upregulated on activated CD4+ T cells, and thus is not a specific marker for T\textsubscript{Reg} cells, we sought to determine the frequency of T\textsubscript{Reg} cells using more specific phenotypes. First, we analyzed the frequency of CD4+CD25\textsuperscript{high} T cells, known to be composed mainly of T\textsubscript{Reg} cells [45], and no significant difference in the frequency of T\textsubscript{Reg} cells could be found between controls and HTLV-1 subjects (Fig. 2E). We determined the intracellular expression of CTLA-4 in CD4+CD25+, and CD4+CD25\textsuperscript{high} T cells and observed a decrease in frequency of CTLA-4+ from HAM/TSP patients (Fig. 2F and 2G). Next, we assessed the expression of CD127. HAM/TSP patients had a statistically significant increase in the frequency of CD4+CD25+CD127\textsuperscript{low} T cells compared to Controls (Fig. 2H). In contrast, there was a slight decrease in frequency of CD4+CD25\textsuperscript{high}CD127\textsuperscript{low} T cells in HTLV-1 infected groups, although this did not reach statistical significance (Fig. 2I). There were no differences in percent expression of GITR between the groups (Fig. 2J, 2K).

Decreased CTLA-4+ T\textsubscript{Reg} cells correlate with increased CD4+ T cell proliferation in HAM/TSP patients

Our initial analysis indicated that the frequency of CD4+CD25+CD127\textsuperscript{low} T cells was higher in HAM/TSP patients. However, there were a lower percentage of CTLA-4+ T\textsubscript{Reg} cells, indicating that HAM/TSP subjects might have

### Table 1: Characteristics of study subjects.

| Sample | Group | Gender | Age (years) | Proviral Load (copies/1,000 cells) | CD4+ T cells/μl | CD8+ T cells/μl | CD3+ T cells/μl |
|--------|-------|--------|-------------|------------------------------------|----------------|----------------|----------------|
| 101    | Control | Male   | 34          | NA                                 | 690            | 389            | 1220           |
| 102    | Control | Male   | -           | NA                                 | 1116           | 525            | 1649           |
| 103    | Control | Male   | -           | NA                                 | -              | -              | -              |
| 104    | Control | Male   | -           | NA                                 | -              | -              | -              |
| 105    | Control | Female | 31          | NA                                 | -              | -              | -              |
| 106    | Control | Female | 28          | NA                                 | -              | -              | -              |
| 107    | Control | Male   | 49          | NA                                 | 917            | 233            | 1235           |
| 201    | HTLV+  | Female | 23          | 60                                 | 1321           | 619            | 1970           |
| 202    | HTLV+  | Female | 49          | 183                                | 710            | 700            | 1402           |
| 203    | HTLV+  | Male   | 40          | 314                                | 749            | 494            | 1248           |
| 204    | HTLV+  | Female | 33          | 120                                | 705            | 227            | 934            |
| 205    | HTLV+  | Female | 66          | 110                                | 1274           | 622            | 1909           |
| 206    | HTLV+  | Female | 31          | 160                                | 904            | 527            | 1500           |
| 209    | HTLV+  | Female | 33          | 7                                   | 1320           | 496            | 1831           |
| 212    | HTLV+  | Male   | 31          | 19                                  | 535            | 251            | 782            |
| 213    | HTLV+  | Female | 37          | 7                                   | 723            | 373            | 1092           |
| 214    | HTLV+  | Male   | 62          | -                                   | 1012           | 242            | 242            |
| 301    | HAM/TSP| Female | 47          | 723                                | 727            | 356            | 1076           |
| 302    | HAM/TSP| Female | 54          | -                                   | 1012           | 242            | 242            |
| 303    | HAM/TSP| Male   | 30          | -                                   | -              | -              | -              |
| 304    | HAM/TSP| Female | 56          | Undetectable                       | 727            | 356            | 1076           |
| 305    | HAM/TSP| Female | 50          | 75                                  | 563            | 327            | 972            |
| 306    | HAM/TSP| Female | 26          | 151                                | 881            | 334            | 1272           |
| 307    | HAM/TSP| Female | 43          | Undetectable                       | 899            | 500            | 1472           |
| 308    | HAM/TSP| Female | 55          | 433                                | 1154           | 478            | 1694           |
| 309    | HAM/TSP| Female | NA          | 175                                | 614            | 165            | 520            |
| 310    | HAM/TSP| Female | 34          | 565                                | 734            | 286            | 1039           |
Expression of Ki-67, HLA-DR and spontaneous production of IFN\(\gamma\) by CD4\(^+\) T cells from Control, HTLV and HAM/TSP subjects. (A) Representative dot plots showing Ki-67 expression in CD4\(^+\) T cells from a Control, a HTLV, and a HAM/TSP subject. (B) Representative dot plots showing spontaneous IFN\(\gamma\) production by CD4\(^+\) T cells. (C) Percent CD4\(^+\)Ki-67\(^+\) T cells; and (D) percent CD4\(^+\)IFN\(\gamma\)^+ T cells; or (E) percent CD4\(^+\)HLA-DR\(^+\) T cells from Control, HTLV, or HAM/TSP. The line shown represents the mean.
Figure 2
Immunophenotypes of CD25\(^{+}\) or CD25\(^{\text{high}}\) CD4\(^{+}\) T cells in Control, HTLV, or HAM/TSP subjects. Dot plots depict the gating strategies for CD25\(^{+}\) and CD25\(^{\text{high}}\) cells (A); CD127\(^{\text{low}}\) (B); and CTLA-4 expression (C) are shown. The gates for CD25\(^{+}\) and CD4\(^{+}\)CD25\(^{\text{high}}\) T cells were set based on the expression level of CD25 on CD4\(^{-}\) T cells, where the pattern of CD25 expression is more distinct. Accordingly, CD4\(^{+}\)CD25\(^{\text{high}}\) T cells were defined as those expressing CD25 at a level higher than the bulk CD4 CD25\(^{+}\) population. For D-K, individual results are represented in symbols, and the line represents the mean. (D) % CD4 CD25\(^{+}\) T cells; (E) % CD4 CD25\(^{\text{high}}\) T cells; (F) % CD4 CD25\(^{+}\)CD127\(^{\text{low}}\) T cells; (G) % of CD4 CD25\(^{\text{high}}\) T cells; (H) % CD4 CD25\(^{+}\)CD127\(^{\text{low}}\) T cells; (I) % CD4 CD25\(^{\text{high}}\)GITR\(^{+}\) T cells; (J) % CD4 CD25\(^{\text{high}}\)GITR\(^{+}\) T cells; (K) % CD4 CD25\(^{\text{high}}\)GITR\(^{+}\) T cells.
of the FOXP3, which presence is associated with TReg cells. To test whether the higher frequency of $T_{\text{Reg}}$ cells was associated with lower levels of activation or proliferation of CD4$^+$ T cells, we compared the frequency of CTLA-4$^+$, CD127$^{\text{low}}$ or GITR$^+$ $T_{\text{Reg}}$ cells with the percentage of CD4$^+$Ki-67$^+$ T cells in HTLV-1 infected subjects (Fig. 3B). There was no association between GITR$^+$ $T_{\text{Reg}}$ cells with the percentage of CD4$^+$Ki-67$^+$ T cells in controls, whereas no such correlation was found in HTLV-1 infected subjects (Fig. 3B). There was no association between GITR$^+$ $T_{\text{Reg}}$ cells with the percentage of CD4$^+$Ki-67$^+$ T cells in any group (Fig. 3C).

The frequency of CD4$^+$CD25$^+$CTLA-4$^+$ and CD127$^{\text{low}}$ $T_{\text{Reg}}$ cells was negatively correlated to HTLV-1 proviral load

Finally, we wanted to determine whether the frequency of $T_{\text{Reg}}$ cells was related to HTLV-1 proviral load. High CD4$^+$ T cells activation and elevated HTLV-1 proviral load are observed in HAM/TSP. We hypothesized that this phenomenon would be related to a lower proportion of $T_{\text{Reg}}$ cells. We quantified HTLV-1 proviral load by real-time PCR and correlated it with the frequency of the different CD25-expressing CD4$^+$ T cell subsets. There was no correlation between the frequency of CD4$^+$CD25$^+$ or CD4$^+$CD25$^{\text{high}}$ T cells with proviral load (Fig. 4A and 4B). In contrast, there was a negative correlation between the frequency of CD4$^+$CD25$^+$CTLA-4$^+$ T cells and proviral load in HTLV only (Fig. 4C). Moreover, there was an inverse correlation between CD127$^{\text{low}}$ $T_{\text{Reg}}$ cells and HTLV-1 proviral load (Fig. 4F).

Discussion

Regulatory T cells are important for the maintenance of peripheral T cell tolerance to self antigens, and can also suppress T cell responses to tumors, parasites, viruses and bacteria. In this study we addressed the relationship between $T_{\text{Reg}}$ cells, T cell activation, and HTLV-1 proviral load. Infection with HTLV-1 was associated with higher spontaneous IFN$\gamma$ release by CD4$^+$ T cells, but only in HAM/TSP there was a marked increase in T cell proliferation.

The HTLV-1 derived tax protein can downregulate expression of the FOXP3, which presence is associated with $T_{\text{Reg}}$ cell function [43,44]. Increased expression of tax can be expected in patients with HAM/TSP, who have higher proviral loads compared to asymptomatic carries. We observed a higher proportion of CD4$^+$ IFN$\gamma$$^+$ T cells in HTLV-1 infected subjects, which could also be indicative of a decreased $T_{\text{Reg}}$ cell fraction. Interestingly, only the HAM/TSP patients presented with a higher cell proliferation, as measured by Ki-67 staining, which correlated markedly with HTLV-1 proviral load (data not shown). These observations suggest that HTLV-1 directly affects $T_{\text{Reg}}$ cell number, and as proviral load increases, not only is the control of IFN$\gamma$ lost, but controls on cell proliferation as well. Our data, together with the recent findings that HTLV-1 tax downregulates FOXP3 expression, indicate that $T_{\text{Reg}}$ cell dysfunction can be a direct consequence of HTLV-1 infection.

In order to better understand the role of $T_{\text{Reg}}$ cells in HTLV-1 infection and disease, we used CTLA-4 and CD127 staining in CD4$^+$CD25$^{\text{high}}$ cells as markers for $T_{\text{Reg}}$ subsets. CD127 and CTLA-4 have been described as useful markers for $T_{\text{Reg}}$ and facilitate the identification of $T_{\text{Reg}}$ cells, even in controls correlated negatively with CD4$^+$ T cell proliferation (Ki-67), indicating that these cells indeed have a regulatory immunophenotype. In contrast, increased frequency of these cells correlated with increased CD4$^+$ T cell proliferation in HTLV-1 infected individuals, suggesting that these cells are not regulatory T cells in these individuals. In addition, the elevated frequency of CTLA-4$^+$ $T_{\text{Reg}}$ cells was negatively correlated to CD4$^+$ T cell proliferation only in HAM/TSP patients, which suggest that it is a better immunophenotype of $T_{\text{Reg}}$ cells in HAM/TSP patients, but more studies are necessary to confirm this.

We could detect a negative association between the frequency of CTLA-4$^+$ or CD127$^{\text{low}}$ $T_{\text{Reg}}$ cells and proviral load, extending recent findings of an association between FOXP3 expression and HTLV-1 infection [44]. We speculate that therapeutic manipulation of regulatory T cells could positively impact disease pathogenesis. Two mechanisms might be involved, the first by suppressing the exuberant anti-HTLV-1 CD8$^+$ T cell mediated immune response, and the second by suppression of CD4$^+$ T cell proliferation, which can result in lower proviral load. However, stimulating an expansion of $T_{\text{Reg}}$ cells could also provide additional targets for HTLV-1 replication, so such studies should proceed with great caution.

In this study, there are some limitations. The study was cross sectional, and with a limited number of patients in each group. We hope that future longitudinal studies can assess changes in $T_{\text{Reg}}$ cells over time in HTLV-1 infected patients. We, and others, working in the regulatory T cells field, are limited by the lack of definitive phenotypic markers of $T_{\text{Reg}}$ and CD4$^+$CD25$^{\text{high}}$ remains the standard identifiers. In this study we have added other markers, but at the time the study was conducted, the FOXP3 antibody, commonly used to detect a $T_{\text{Reg}}$ cell population was not commercially available. However, this may have been
Correlation between different immunophenotypes of T<sub>reg</sub> with expression of Ki-67. Frequency of CTLA-4<sup>+</sup>, CD127<sub>low</sub>, or GITR<sup>+</sup> T<sub>reg</sub> were correlated with proportion of CD4<sup>+</sup>Ki67<sup>+</sup> T cells in Control (Blue diamond), HTLV (Green triangle) and HAM/TSP (Red circle). A. There was a negative correlation between CTLA-4<sup>+</sup> T<sub>reg</sub> with percentage of CD4<sup>+</sup>Ki67<sup>+</sup> T cells in HAM/TSP only (r = -0.7833, p = 0.017). B. CD127<sub>low</sub> T<sub>reg</sub> were inversely correlated with proportion of CD4<sup>+</sup>Ki67<sup>+</sup> T cells in Control group (r = -0.8108, p = 0.034). C. There was no association between GITR<sup>+</sup> T<sub>reg</sub> with percentage of CD4<sup>+</sup>Ki67<sup>+</sup> T cells in any group.

Figure 3
Figure 4
Correlation between HTLV-I proviral load of HTLV (Green triangle), and HAM/TSP (Red circle) with expression of CD127 or CTLA-4 in CD25\(^+\) or CD25\(^{\text{high}}\) CD4\(^+\) T cells subsets. HTLV-I proviral load is expressed in copies per 1,000 cells. There was no correlation with CD4\(^+\)CD25\(^+\) T cells (A). No correlation with CD4\(^+\)CD25\(^{\text{high}}\) T cells (B). Inverse correlation with the percentage of CD4\(^+\)CD25\(^+\)CTLA-4\(^+\) T cells in HTLV only; \(r = -0.7500, p = 0.0255\) (C). No correlation with CD4\(^+\)CD25\(^{\text{high}}\)CTLA-4\(^+\) T cells (D). Lack of correlation with the percentage of CD4\(^+\)CD25\(^+\)CD127\(^{\text{low}}\) T cells (E). (F) Negative correlation with CD4\(^+\)CD25\(^{\text{high}}\)CD127\(^{\text{low}}\) T cells in HTLV \((r = -0.7333, p = 0.03)\) and HAM/TSP \((r = -0.8108, p = 0.034)\).
a fortuitous event, as recent reports suggest that FOXP3 is also expressed on non regulatory T cells in humans [46,47]. As we did not have access to tissue samples from these subjects, we cannot exclude redistribution of cells out of the peripheral blood into tissues, and the study of regulatory T cells at secondary lymphoid sites and within CSF will be of interest for a future study of HTLV-1 associated disease.

In conclusion, our data suggest a role of T<sub>reg</sub> cells in the pathogenesis of HAM/TSP. Further studies should help delineate the ability of expanded T<sub>reg</sub> cells to affect T cell proliferation in HTLV-1 patients and the potential development of therapeutic modulation of regulatory T cells in HTLV-1 patients.

Conclusion
In this study, we showed that HTLV-1 drives activation, spontaneous IFNγ production, and proliferation of CD4+ T cells. HAM/TSP patients have a decreased frequency of T<sub>reg</sub> cells in peripheral blood, compared to healthy subjects, markedly in the CD4<sup>+</sup>CD25<sup>high</sup>CTLA-4 phenotype. The proportion of CD127<sup>low</sup>T<sub>reg</sub> cells correlated inversely with HTLV-1 proviral load. These results suggest that T<sub>reg</sub> cells may be subverted in HAM/TSP patients, and contributes to the identification of novel therapeutic targets for patients with HTLV-1-related disease.

Methods
Study subjects
Three groups of volunteers were enrolled. The first consisted of seven HTLV-1-negative control volunteers; the second consisted of ten HTLV-1 seropositive volunteers without clinical and laboratory evidence of HTLV-1-associated disease, and the last group was composed of nine patients with the diagnosis of HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). After approval by the Institutional Review Board, written informed consent was obtained from all the participants according to the guidelines of Brazilian Ministry of Health. Samples were collected in EDTA-treated vacuum tubes, and PBMC were frozen into liquid nitrogen after separation using a ficoll gradient.

DNA extraction and determination of HTLV-1 proviral load
HTLV-1 proviral DNA was extracted from PBMC using a commercial kit (Qiagen GmbH, Hilden Germany) following the manufacturer's instructions. The extracted DNA was used as a template to amplify a fragment of 158 bp from the viral tax region using previously published primers [48]. The SYBR green real-time PCR assay was carried out in 25 μl PCR mixture containing 10× Tris (pH 8.3; Invitrogen, Brazil), 1.5 mM MgCl<sub>2</sub>, 0.2 μM of each primer, 0.2 mM of each dNTPs, SYBR Green (18.75 Units/r × n; Cambrex Bio Science, Rockland, ME) and 1 unit of platinum Taq polymerase (Invitrogen, Brazil). The amplification was performed in the Bio-Rad iCycler iQ system using an initial denaturation step at 95°C for 2 minutes, followed by 50 cycles of 95°C for 30 seconds, 57°C for 30 seconds and 72°C for 30 seconds. The human housekeeping β globin gene primers GH20 and PC04 [49] were used as an internal control calibrator. For each run, standard curves for the value of HTLV-1 tax were generated from MT-2 cells of log<sub>10</sub> dilutions (from 10<sup>5</sup> to 10<sup>9</sup> copy). The threshold cycle for each clinical sample was calculated by defining the point at which the fluorescence exceeded a threshold limit. Each sample was assayed in duplicate and the mean of the two values was considered as the copy number of the sample. The amount of HTLV-1 proviral load was calculated as follows: copy number of HTLV-1 (tax) per 1,000 cells = (copy number of HTLV-1 tax)/(copy number of β globin/2) × 1000 cells. The method could detect 1 copy per 10<sup>3</sup> PBMCs cells.

Flow cytometry
PBMCs were thawed and stained with directly conjugated antibodies. Three different panels of antibodies were used to evaluate the expression of proteins associated with T<sub>reg</sub> cells and T cell activation. All antibodies were from BD Biosciences, unless otherwise noted. All panels contained PerCP-conjugated anti-CD4 and allophycocyanin-conjugated anti-CD25, and in addition contained (1) FITC-conjugated anti-GITR and PE-conjugated anti-CD127 (Beckman Coulter, Miami, FL), (2) FITC-conjugated anti-CD45RA and PE-conjugated anti-HLA-DR and (3) FITC-conjugated anti-Ki-67 and PE-conjugated anti-CD152 (CTLA-4). Cells stained with PerCP-conjugated anti-CD4 alone and allophycocyanin-conjugated CD25 alone were used to establish positive gates for FITC- and PE-conjugated antibodies. For panel 1 and 2, cells were stained with all antibodies in PBS supplemented with 0.5% bovine serum albumin (BSA) and 2 mM EDTA (FACS buffer), followed by two washes in FACS buffer and fixation in 1% paraformaldehyde (PFA). For panel 3, cells were first stained with PerCP-conjugated anti-CD4 and allophycocyanin-conjugated anti-CD25, followed by two washes in FACS buffer and fixation in 1% PFA. The cells were subsequently washed twice with PBS containing 0.1% saponin (perm buffer), prior to staining with PE-conjugated anti-CD152 and FITC-conjugated anti-Ki-67 diluted in perm buffer. All samples were analyzed on a FACS Calibur flow cytometer (Becton Dickinson) equipped with a 488 nm argon and a 633 nm red-diode lasers for four color detection. Acquisition and analyses were performed using CellQuest software (Becton Dickinson). Fluorescence voltages and compensation values were determined using unstained cells and cells single-stained with each of the fluorochrome-conjugated antibodies, respectively. The gating strategy used was to gate
on lymphocytes using a forward scatter versus side scatter gate, followed by gating on CD4⁺ cells. The gate for CD4⁺-CD25⁺ cells was set using cells stained with the PerCP-conjugated anti-CD4 antibody alone. Positive gates for the FITC- and PE-conjugated antibodies were set using cells stained with only PerCP-conjugated anti-CD4 and APC-conjugated anti-CD25 antibodies.

Cytokine flow cytometry
PBMCs were thawed and cultured for 24 hours in 96-well U-bottom plates at a concentration of 4 × 10⁵ cells/well. Brefeldin A (BFA) was added at a concentration of 5 μg/ml for the last 5 hours of the culture. After culture, cells were harvested, stained with PE-conjugated anti-CD4, fixed in 4% PFA for 20 min, prior to being washed twice with perm buffer. The cells were subsequently stained with PerCP-conjugated anti-CD3 and allophycocyanin-conjugated anti-IFNγ, washed twice in perm buffer and resuspended in FACS buffer, prior to being analyzed on a FACScalibur. All antibodies were from BD Biosciences.

Statistical analyses
Data sets were compiled and analyzed in Statistica, release 6.0 (Statsoft, Tulsa, OK) and Prism, release 4.0 (GraphPad Software, San Diego, CA). Groups comparisons were performed using non-parametric Kruskal Wallis ANOVA by ranks test; associations between variables were evaluated by Spearman rank order correlation's test. Critical p values were considered statistically significant if below 0.05.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
JM planned and conducted the experiments, performed the statistical analyses, and wrote the manuscript; HMRRB wrote the original protocol, collected the samples, prepared the database, helped in the experiments, performed statistical analyses, and wrote the manuscript; KAJ conducted the experiments and helped in the flow cytometry analyses; JMC conducted the experiments and helped in the flow cytometry analyses; MKCB conducted the experiments and helped in the flow cytometry analyses; WKN performed the HTLV-I viral load; YN supported the protocol design and the conduction of HTLV-I viral load; ECS performed the HTLV-I serology, helped in the project design, the molecular biology experiments, and writing the manuscript; MAC selected subjects for the cohort and supervised the blood collection of samples from HAM/TSP patients; ASBO selected subjects for the cohort and supervised the blood collection of samples from HAM/TSP patients; DFN participated in the experimental design, obtained funds for the project, discussed the results, and wrote the manuscript; ECK wrote the original protocol, participated in the experimental design, obtained funds for the project, discussed the results, and wrote the manuscript.

Acknowledgements
We would like to thank Marli Campos, Rosemerei Gabriel, and Perpétua for the assistance in blood collection, and Dr. Lishomwa Ndhloulo for helpful scientific discussions. We are also grateful to Karina I. Carvalho, Helena Tomyiama, and Raphaela Goulart for the continuous laboratory support. This work was supported by the Fundação de Amparo a Pesquisa do Estado de São Paulo (Fapesp), grant #04/10918-6, NIH grants (AI141531, AI52731, AI060379, AI064520), and The Fogarty International Center, grant #D43 TW00003. Dr. Barbosa and Ms. Bruniai were supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazilian Ministry of Education.

References
1. Edlich RF, Hill LG, Williams FM: Global epidemic of human T-cell lymphotrophic virus type-I (HTLV-I): an update. J Long Term Eff Med Implants 2003, 13(2):127-140.
2. Tajima K: The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. Int J Cancer 1990, 45(2):237-243.
3. Edlich RF, Arnette JA, Williams FM: Global epidemic of human T-cell lymphotrophic virus type-I (HTLV-I). J Emerg Med 2000, 18(1):109-119.
4. Gotuzzo E, Arango C, de Queiroz-Campos A, Istawiz RE: Human T-cell lymphotrophic virus-I in Latin America. Infect Dis Clin North Am 2000, 14(1):21-39, x-xi.
5. Carneiro-Proietti AB, Ribas JG, Catalan-Soares BC, Martins ML, Brito-Melo GE, Martins-Filho OA, Pinheiro SR, Araujo Ade Q, Galvao-Castro B, de Oliveira MS, Guedes AC, Proietti FA: Infection and disease caused by the human T cell lymphotrophic viruses type I and II in Brazil. Rev Soc Bras Med Trop 2002, 35(5):499-508.
6. Farias de Carvalho SM, Pombo de Oliveira MS, Thuler LC, Rios M, Coelho RC, Rubim LC, Silva EM, Reis AM, Catovsky D: HTLV-I and HTLV-II infections in hematologic disorder patients, cancer patients, and healthy individuals from Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 15(3):238-242.
7. Galvao-Castro B, Loures L, Rodrigues LG, Sereno A, Ferreira Junior OC, Franco LG, Muller M, Sampaio DA, Santana A, Passos LM, Proietti F: Distribution of human T lymphotrophic virus type 1 among blood donors: a nationwide Brazilian study. Transfusion 1997, 37(2):242-243.
8. Segurado AA, Malaque CM, Sumita LM, Pannuti CS, Lal RB: Laboratory characterization of human T cell lymphotrophic virus types I (HTLV-I) and 2 (HTLV-2) infections in blood donors from Sao Paulo, Brazil. Am J Trop Med Hyg 1997, 57(2):142-148.
9. Mariner JM, Lantz V, Waldmann TA, Azimi N: Human T cell lymphotrophic virus type I Tax activates IL-15R alpha gene expression through an NF-kappa B site. J Immunol 2001, 166(4):2602-2609.
10. Azimi N, Brown K, Bamford RN, Tagaya Y, Siebenlist U, Waldmann TA: Human T cell lymphotrophic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site. Proc Natl Acad Sci U S A 1998, 95(5):2452-2457.
11. Ballard DW, Bohnlein E, Lowenthal JW, Wano Y, Franza BR, Greene WC: HTLV-I Tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene. Science 1988, 241(4873):1652-1655.
12. Crenon I, Beraud C, Simard P, Montagne J, Veschembre P, Jaline L: The transcriptionally active factors mediating the effect of the HTLV-I Tax transactivator on the IL-2R alpha kappa B enhancer include the product of the c-rel proto-oncogene. Oncogene 1993, 8(4):867-875.
13. Good L, Maggirwar SB, Sun SC: Activation of the IL-2 gene promoter by HTLV-I Tax involves induction of NF-AT complexes bound to the CD28-responsive element. Embryo J 1996, 15(14):3744-3750.
14. Kao SY, Marriott SJ: Disruption of nucleotide excision repair by the human T cell leukemia virus type 1 Tax protein. *J Virol* 1996, 70(3):1421-1428.

15. Laihty CD, Perkins ND, Dixit VM: Human T cell leukemia virus type 1 Tax and phorbol 12-myristate 13-acetate induce expression of the A20 zinc finger protein by distinct mechanisms involving nuclear factor kappa B. *J Biol Chem* 1993, 268(7):5032-5039.

16. Brauwender A, Gurus JE, Reed JC, Nyborg JK: Repression of bax gene expression by the HTLV-I Tax protein: implications for suppression of apoptosis in virally infected cells. *Virology* 1997, 231(1):135-140.

17. Flomenboel GN, Giebler HA, Reisman D, Nyborg JK: Transcriptional repression of p53 by human T-cell leukemia virus type 1 Tax protein. *J Biol Chem* 1995, 270(48):28503-28505.

18. Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, Hashiguchi S, Ichinose M, Bangham CR, Izumo S, Osame M: Antigenic control of human T lymphotropic virus type I infection. *J Immunol* 2000, 165(12):7278-7284.

19. Jeffery KJ, Siddiqui AA, Bunce M, Lloyd AL, Vine AM, Witkowski AD, Izumo S, Usuku K, Walsh KJ, Osame M, Bangham CR: The influence of HLA class I alleles and heterozygosity on the outcome of human T lymphotropic virus type 1 infection. *J Immunol* 2002, 168(6):3031-3039.

20. Sabouri AH, Saito M, Lloyd AL, Piccirillo A, Meggiolaro A, Wang SF, Yang W, Venet A, Powell R, Maelicke A, Eischen C, Jaffe E, Li Y, Pazin MJ, Sadelain M, Heyman L, Tiraby G, Ho DD, Edinger M, Kortepeter ME, Yang G, Hengartner MF, Johnson WE, Pamer EG, Wang X, Shiku H, Usuku K, Bangham CR: CD4+CD25+ T cells in cell lines of human adult T-cell leukemia virus type I. Blood 1996, 87(6):135-140.

21. Jeffery KJ, Siddiqui AA, Bunce M, Hall SE, Matsumoto W, Taylor GP, Procter J, Bunce M, Ogg GS, Welsh KJ, Weiher JJ, Lloyd AL, Nowak MA, Nagai M, Kodama D, Izumo S, Osame M, Bangham CR: HALA alleles determine human T lymphotropic virus-1 (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. *Proc Natl Acad Sci U S A* 1999, 96(7):3848-3853.

22. Vine AM, Witkowski AD, Lloyd AL, Jeffery KJ, Siddiqui A, Marshall SE, Bunce M, Iriau N, Izumo S, Usuku K, Osame M, Bangham CR: Polyclonal control of human T lymphotropic virus type 1 (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. *Proc Natl Acad Sci U S A* 1999, 96(7):3848-3853.

23. Lim DG, Bieganowska Bourcier K, Freeman GJ, Hafler DA: Reduced Foxp3 protein expression is associated with inflammatory disease during human T lymphotropic virus type 1 infection. *Proc Natl Acad Sci U S A* 1999, 96(7):3848-3853.

24. Bunce M, Fox BC, Brown PJ, Worthington J, Fox SB, Chapman RW, Fleming KA, Banham AH, Klereneman P: Quantification and localisation of FOXP3+ T lymphocytes and regulatory T cells. Blood 2006, 107(11):3929-3939.

25. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA: CD127 expression inversely correlates with Foxp3 and suppressive function of human CD4+ T regulatory cells. *J Exp Med* 2006, 203(7):1701-1711.

26. Read S, Malmstrom V, Powrie F: Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory T cells that control intestinal inflammation. *J Hepatol* 2007.

27. Takahashi A, Tagge T, Yamakami S, Uede T, Shimizu J, Takahashi T, Nomura T: Analysis of HTLV-I proviral load and the risk of HTLV-I-associated myelopathy/tropical spastic paraparesis. *Microbes Infect* 2004, 6:293-301.

28. Greenberg PD, Stromnes IM, Iwashiro M, Sakaguchi S, Evans LH, Pederek KE, Yang G, Hengartner MF, Johnson WE, Pamer EG, Wang X, Shiku H, Usuku K, Bangham CR: HALA alleles determine human T lymphotropic virus type 1 infection. *J Immunol* 2000, 165(12):7278-7284.

29. Tanaka Y, Tozawa H, Koyanagi Y, Shida H: Recognition of human T cell leukemia virus type 1 (HTLV-I1) gag and pX gene products by MHC-restricted cytotoxic T lymphocytes induced in rats against syngeneic HTLV-I-infected cells. *J Immunol* 1990, 144(1):420-421.

30. Jacobson S, Reuben JS, Streilein JD, Palker TJ: Induction of CD4+ human T lymphotropic virus type-1-specific cytotoxic T lymphocyte responses in patients with HTLV. *J Immunol* 1991, 146(4):1151-1162.

31. Koyama I, Shimizu M, Igarashi H, Kuruma K, Murai H, Aono Y, Murayama I, Osame M, Hattori T, Inoko H, et al.: Target epitope in the Tax protein of human T cell leukemia virus type I recognized by class I major histocompatibility complex-restricted cytotoxic T cells. *J Virol* 1992, 66(5):2928-2933.

32. Daeche S, Kermode AG, Hall SE, Taylor G, Weber J, Nightingale S, Bangham CR: High activated and memory cytotoxic T-cell responses to HTLV-I in healthy carriers and patients with tropical spastic paraparesis. *Virology* 1996, 217(1):139-146.

33. Kozako T, Arima N, Toji S, Masamato I, Akimoto M, Hamada H, Che XF, Fujiiwa H, Matsushita K, Tokunaga M, Haraguchi K, Uozumi K, Suzuki S, Takezaki T, Sonoda S: Reduced frequency, diversity, and function of human T cell leukemia virus type 1-specific CD8+ T cell in adult T cell leukemia patients. *J Immunol* 2006, 177(6):5718-5726.
47. Wang J, Ioan-Facsinay A, van der Voort El, Huizinga TW, Toes RE: Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. *Eur J Immunol* 2007, 37(1):129-138.

48. Innis MA: PCR protocols: a guide to methods and applications. San Diego, Academic Press; 1990:xviii, 482 p.

49. Iannone R, Sherman MP, Rodgers-Johnson PE, Beilke MA, Mora CA, Amin RM, Tinsley SR, Papsidero LD, Poiesz BJ, Gibbs CJ Jr: HTLV-I DNA sequences in CNS tissue of a patient with tropical spastic paraparesis and HTLV-I-associated myelopathy. *J Acquir Immune Defic Syndr* 1992, 5(8):810-816.